MIRA Pharmaceuticals Announces Promising Data for Ketamir-2
MIRA's Ketamir-2 shows promise for treating neurological conditions, with faster brain absorption.
Leading preclinical-stage pharmaceutical business MIRA
Pharmaceuticals has released fresh preclinical research data for Ketamir-2, a
novel oral ketamine analogue.
As MIRA works towards submitting an Investigational New Drug
(IND) application to the U.S. Food and Drug Administration (FDA) by the end of
this year, which, if granted, would allow for human testing of Ketamir-2, the
additional data announced today continues a string of promising preclinical
results announced by MIRA in recent months for Ketamir-2.The potential of
ketamir-2 to treat neurological and neuropsychiatric conditions such as
depression, treatment-resistant depression (TRD), and post-traumatic stress
disorder (PTSD) is being studied.
In vitro research has shown that ketamir-2 is not a
substrate for P-glycoprotein (P-gp), a membrane protein that normally pumps a
variety of medications out of cells, including brain cells. This feature may
help Ketamir-2, a P-gp substrate, absorb more readily via the mouth and cross
the blood-brain barrier more quickly than conventional ketamine.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
Pharming Group Gains FDA Approval for Leniolisib in Children Aged 4–11 with APDS
Lonza Builds Oregon Spray-Drying Facility To Expand SDD Capacity
Discussion